TransMedics Group Inc Cash Flow Conversion Efficiency
TransMedics Group Inc cash flow conversion efficiency. Based on the latest financial reports, TransMedics Group Inc (TMDX) has a cash flow conversion efficiency ratio of 0.033x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($17.31 Million) by net assets ($518.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of TransMedics Group Inc (2006–2025)
Cash flow conversion efficiency of TransMedics Group Inc from 2006 to 2025. This chart illustrates how TransMedics Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for TransMedics Group Inc for real-time trading data and today's change.
TransMedics Group Inc Cash Flow Conversion Ratio Explained
TransMedics Group Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
TransMedics Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TransMedics Group Inc ranked by their cash flow conversion efficiency. Also see how much is TransMedics Group Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Dongfang Precision Science & Technology Co Ltd
SHE:002611
|
0.037x |
|
Accelerant Holdings
NYSE:ARX
|
-0.030x |
|
Teekay Tankers Ltd
NYSE:TNK
|
0.039x |
|
Wuxi Taclink Optoelectronics Technology Co. Ltd. A
SHG:688205
|
N/A |
|
Micro Tech Nanjing Co Ltd
SHG:688029
|
0.040x |
|
Tibet GaoZheng Explosive Co Ltd
SHE:002827
|
0.036x |
|
Ternium Argentina SA
BA:TXAR
|
0.014x |
|
Enerflex Ltd.
TO:EFX
|
0.046x |
Annual Cash Flow Conversion Efficiency for TransMedics Group Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of TransMedics Group Inc from 2006 to 2025. Review TransMedics Group Inc (TMDX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $473.10 Million | $192.84 Million | 0.408x | +90.93% |
| 2024-12-31 | $228.60 Million | $48.80 Million | 0.213x | +324.83% |
| 2023-12-31 | $137.20 Million | $-13.03 Million | -0.095x | +61.17% |
| 2022-12-31 | $187.38 Million | $-45.82 Million | -0.245x | +42.52% |
| 2021-12-31 | $67.85 Million | $-28.86 Million | -0.425x | -46.02% |
| 2020-12-31 | $103.89 Million | $-30.27 Million | -0.291x | +50.69% |
| 2019-12-31 | $54.65 Million | $-32.29 Million | -0.591x | -110.97% |
| 2018-12-31 | $-4.83 Million | $-25.98 Million | 5.385x | +3833.79% |
| 2017-12-31 | $-168.72 Million | $-23.10 Million | 0.137x | +122.03% |
| 2016-12-31 | $38.79 Million | $-24.11 Million | -0.622x | +66.36% |
| 2006-12-31 | $8.80 Million | $-16.27 Million | -1.847x | -- |
About TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic con… Read more